Cannamedical Pharma

What Cannamedical Pharma does

Cannamedical Pharma GmbH is a Cologne-based, independent wholesaler of medical cannabis flowers and extracts serving the German and broader EU pharmaceutical market. Founded in November 2016 by David Henn and integrated into the Semdor Pharma Group in 2021, the company operates under a pharmaceutical quality stack: it holds GDP certification itself while its grower and manufacturing partners worldwide are GMP-certified, with GACP-compliant imports and a batch-level Freigabezertifikat issued for every product released to pharmacy and clinical customers. Its product portfolio is organized around a proprietary THC tier system (light, classic, forte, ultra) covering Indica, Sativa and Hybrid genetics in 15g formats, standardized extracts such as THC10/CBD10 oils, and two newer sub-brands: the premium craft line CM CRAFT (launched December 2025) and the high-potency Cannamedical Ultimate tier anchored by Afghan Bubba Kush (~26-35% THC, launched March 2026).

The company runs a multi-channel go-to-market: a §10-HWG-compliant, login-gated B2B webshop for pharmacies and clinical institutions with tiered logistics (standard, Saturday, next-day, express), a public B2C webshop for German private customers, and the CannAcademy continuing-education program that trains roughly 2,000 physicians and pharmacists per year via live webinars (~100 attendees each) and on-demand content (~350 monthly views). Revenue mechanics are predominantly unit-priced B2B wholesale to German pharmacies plus EU-wide distribution to clinical institutions, supplemented by ancillary logistics surcharges (€9.95 sub-threshold shipping, €25 returns/Saturday/next-day, €27 express) and B2C webshop transactions payable by invoice, credit card or PayPal.

Cannamedical positions itself as a long-term partner to pharmacies and clinical institutions, supplementing supply with the gated Fachbereich portal (release certificates, ESCAPE study, dosing tools), a public Ratgeber content hub, weekly newsletter segmentation, scientific collaborations (e.g., Prof. Dr. Sylvia Mechsner at Charité Berlin on endometriosis), and brand-building initiatives such as the April 2026 Hauptsponsorship of the German Boxing Series.

Name

Cannamedical Pharma

Legal name

Cannamedical® Pharma GmbH

Website

https://cannamedical.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Cannamedical Pharma GmbH is a Cologne-based independent wholesaler of GMP-certified medical cannabis flowers and extracts, distributing to German pharmacies and EU clinical institutions via a B2B portal and to patients via a webshop, supported by the CannAcademy prescriber education program.

Ownership category

akta.pro rank

Product category

Medical Cannabis Distribution

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmacies and Drug Retailers (456110)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Medical Cannabis Dispensaries (CRANAFAB)

akta.pro secondary industries

Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG), Cannabis Online Ordering for Dispensary Pickup (Click-and-Collect) (CRANAGAC)

Keywords

• Medical cannabis wholesale
• Pharmaceutical cannabis distribution
• Cannabis flower distribution
• Cannabis extracts supply
• Medical cannabis education

Headquarters

HQ city

Köln

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

1. Wholesale of medical cannabis to pharmacies: Core B2B wholesale of GMP-produced medical cannabis flowers and extracts to German pharmacies (and EU-wide), sold as one-time purchase orders with logistics add-ons (express, Saturday delivery) priced per order.
2. Distribution to clinical institutions: Direct supply to clinics and clinical facilities across the EU; positioning as long-term partner in the healthcare system.
3. Direct-to-consumer webshop sales (B2C): Online webshop for private customers in Germany with payment via invoice, credit card, and PayPal; unit-priced cannabis flowers and extracts.
4. Logistics and service surcharges: Ancillary revenue from delivery surcharges (express, Saturday), return handling, and freight cost pass-throughs on sub-threshold B2B orders.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

Core offering

Cannamedical Pharma imports and distributes GMP-certified medical cannabis flowers (in light, classic, forte, ultra and Ultimate THC tiers) and standardized cannabis extracts, sourced from GMP-certified growers worldwide and released to pharmacies and clinical institutions under its own GDP-certified operations. Sales are conducted primarily through a login-gated B2B webshop for German pharmacies and clinical facilities (with EU-wide wholesale), supplemented by a public direct-to-consumer webshop for German private customers, and supported by the CannAcademy training program for prescribers and pharmacists.

Product overview

Cannamedical Pharma GmbH is a single-vendor specialty pharmaceutical operation organized as a product-line portfolio plus a gated distribution and education platform, not a multi-tenant SaaS. The core offerings are imported and distributed medical cannabis products — Medical Cannabis Flowers (Cannabisblüten, in light/classic/forte/ultra THC tiers), standardized Cannabis Extracts (Cannabisextrakte, e.g., THC10/CBD10), the premium CM CRAFT line, and the recently introduced Cannamedical Ultimate tier anchored by Afghan Bubba Kush. These products are sold through the B2B Shop, a login-restricted ordering platform for pharmacies and clinical facilities, while education and credentialing for physicians/pharmacists are delivered via CannAcademy and the gated Fachbereich (Professional Area / Cannamedical Portal). Public-facing patient education is provided through the Ratgeber content hub and newsletter. Together, the cannabis products, B2B Shop, CannAcademy, Fachbereich, and Ratgeber form an integrated supply-plus-education stack for the German and EU medical cannabis market.

Differentiator

Problem solved

Functional benefit

Brands

• CM CRAFT: An exclusive product line of hand-picked, hand-trimmed, organically grown medical cannabis in strictly controlled, limited batches, with sustainably produced flower and full GMP/GDP-compliant quality assurance.
• CM Ultimate (Cannamedical Ultimate)

Products and services

• Medical Cannabis Flowers (Cannabisblüten) Dried medical cannabis flowers imported from GMP-certified growers worldwide and distributed under GACP/GMP quality standards with documented batch release. Available in four THC-based tiers (light, classic, forte, ultra) plus the new Ultimate tier, across Indica, Sativa and Hybrid genetics, marketed in 15 g doses with documented terpene profiles. Sold to pharmacies and clinical institutions via the B2B shop and to German private customers via the public webshop.
• Cannabis Extracts (Cannabisextrakte) Standardized cannabinoid oil- and alcohol-based extracts for medical use, including balanced THC10/CBD10 formulations, with slower onset and long-lasting effect. Suited to chronic conditions and patient groups needing discrete dosing such as geriatric, palliative and working patients.
• CM CRAFT product line Exclusive craft cannabis product line of hand-picked, hand-trimmed, ecologically cultivated medical cannabis in strictly controlled, limited batches, combining artisanal cultivation with Cannamedical's GMP/GDP pharmaceutical standards. Targeted at discerning patients seeking premium craft cannabis.
• Afghan Bubba Kush (Cannamedical Ultimate tier) First product in Cannamedical's new Ultimate THC tier — an Indica-dominant hybrid flower (Afghan Kush × 8 Ball Kush; 90% Indica / 10% Sativa) with THC ~26–35% and CBD <1%. Terpene profile led by Myrcen, Caryophyllen and Humulen; positioned for evening relaxation and regenerative therapy.
• CannAcademy Continuing-education and training program for medical professionals (physicians and pharmacists) including live webinars, on-demand webinars and conferences on dosing, titration, indications (endometriosis, oncology, sleep, pain) and regulatory frameworks. Used to drive evidence-based prescribing and dispensing pull-through.

Quantifiable outcome

• ~2,000 physicians and pharmacists trained annually through CannAcademy webinars and events in 2025
• +1 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability1 record

Feature5 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• German Boxing Series (GBS)flagshipGTM or Marketing Partner · 22 April 2026Cannamedical Pharma became the official main sponsor (Hauptsponsor) of the German Boxing Series, founded in 2024 in Cologne by Ruben Lammersdorf, Roman Lammersdorf and Jens Kröger. The partnership was announced on 22 April 2026 and includes brand presence at all GBS events plus structural projects to develop young professional boxing talent. Cannamedical also supports two athletes: Gregor Soenius and Younes Zarraa.
• Semdor Pharma GroupflagshipStrategic or Co-development PartnerCannamedical Pharma GmbH has been part of the Semdor Pharma Group since 2021; the parent group owns the company founded by David Henn in 2016.
• Prof. Dr. med. Sylvia Mechsner (Charité Berlin, Endometriosis Center)coreStrategic or Co-development PartnerScientific partner for Cannamedical's endometriosis awareness activities; co-led the 11 March 2026 webinar on cannabinoids in endometriosis and contributed to a study on cannabis use in endometriosis patients at Charité Berlin.
• Dr. Yvonne WagnercoreStrategic or Co-development PartnerCo-presenter for Cannamedical webinars (e.g., endometriosis, oncology topics); former Chief Medical Officer of Cannamedical Pharma GmbH until mid-2023 with nearly 20 years of experience in drug development; medical chemist quoted in Cannamedical oncology press release.
• Urban Sports ClubminorGTM or Marketing PartnerEmployee benefit partner: Cannamedical subsidizes most of the Classic tariff membership for staff; employees contribute €9.90/month.
• FRÖBELminorGTM or Marketing PartnerCooperation giving Cannamedical employees preferential access to kindergarten places.
• Cannazen.deminorGTM or Marketing PartnerAffiliate/banner advertising partner referenced via UTM-tracked banner ads embedded in Cannamedical's Ratgeber articles.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Nimbus Health: German medical cannabis wholesaler focused on pharmacy distribution with a similar B2B shop and prescriber support model.
• Cansativa: German medical cannabis wholesaler and distribution platform supplying pharmacies; competes with Cannamedical on assortment, B2B shop experience and EU reach.
• Demecan: German producer and wholesaler of medical cannabis flowers and extracts serving pharmacies; one of the few Germany-based competitors with cultivation and distribution under a single roof.
• Four 20 Pharma: Germany-based medical cannabis producer-distributor with own GMP cultivation and pharmacy wholesale; competes head-on with Cannamedical on flower supply to German Apotheken.
• Sanity Group: Berlin-based medical cannabis company spanning pharma wholesale (Sanity Pharma) and consumer brands; comparable in German pharmacy-channel focus and product portfolio breadth.

Broad incumbents

• Aurora Cannabis Europe: European arm of Canadian LP Aurora, distributing medical cannabis (including in Germany); broader portfolio but competes in the same German pharmacy channel.
• Tilray Medical: Global medical cannabis business of Tilray Brands with EU distribution and a German footprint; competes in the same pharmacy and clinical channels as Cannamedical.
• Canopy Growth (Germany/Europe): Canadian licensed producer with established European medical cannabis distribution and a Storz & Bickel/Stella distribution setup; large incumbent overlapping Cannamedical's channels.
• STADA Arzneimittel (medical cannabis portfolio): German generics and specialty pharma incumbent that has expanded into medical cannabis distribution; competes as a broader pharma counterparty to Cannamedical in pharmacy supply.

Emerging players

• Bloomwell Group: Frankfurt-based medical cannabis platform combining pharmacy wholesale, telemedicine and consumer delivery; partial overlap with Cannamedical's pharmacy and patient-facing models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCNSWH0TNb8vKe-3t-yCiIHg
• Facebookfacebook.com/CannamedicalPharma
• LinkedInlinkedin.com/company/cannamedical
• Instagraminstagram.com/cannamedicalpharma
• Xx.com/Cannamedical_de

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cannamedical Pharma